Suchergebnisse - "Ziepert, Marita"

PubPharm (130)

51

The impact of SOCS1 mutations in diffuse large B-cell lymphoma

enthalten in: British journal of haematology | 2019

von Mellert, K. | Martin, M. | Lennerz, J. | +15

52

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma : A Study by the Lunenburg Lymphoma Biomarker Consortium

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Rosenwald, A. | Bens, S. | Advani, R. | +33

53

IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications

enthalten in: Virchows Archiv | 2019

von Granai, M. | Amato, T. | Di Napoli, A. | +13

54

IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications

enthalten in: Virchows Archiv | 2019

von Granai, M. | Amato, T. | Di Napoli, A. | +13

55

IGHV mutational status of nodal marginal zone lymphoma by NGS reveals distinct pathogenic pathways with different prognostic implications

enthalten in: Virchows Archiv | 2019

von Granai, M. | Amato, T. | Di Napoli, A. | +13

56

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial

enthalten in: British journal of haematology | 2019

von Friedrichs, B. | Nickelsen, M. | Ziepert, M. | +12

57

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER) : a randomised, phase 3, non-inferiority trial

enthalten in: The lancet | 19 December 2019

von Pöschel, V. | Held, G. | Ziepert, M. | +41

58

Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma

enthalten in: Blood | 2018

von Thurner, L. | Preuss, K. | Bewarder, M. | +26

CommentIn: Blood. 2018 Dec 27;132(26):2704-2706. - PMID 30591542

59

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma : An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Shi, Q. | Schmitz, N. | Ou, F. | +16

CommentIn: J Clin Oncol. 2019 Feb 20;37(6):525-526. - PMID 30592639

60

Author Correction : Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

enthalten in: Nature medicine | 2018

von Chapuy, B. | Stewart, C. | Dunford, A. | +43

ErratumFor: Nat Med. 2018 May;24(5):679-690. - PMID 29713087